+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biosimilar Therapeutic Peptides Global Market Report 2021: COVID-19 Growth and Change to 2030

  • ID: 5446139
  • Report
  • September 2021
  • Region: Global
  • 175 Pages
  • The Business Research Company

FEATURED COMPANIES

  • Amgen Inc.
  • Bachem Holding AG
  • Eli Lilly
  • Hyperion Therapeutics
  • Merck & Co. Inc.
  • PeptiDream
Biosimilar Therapeutic Peptides Global Market Report 2021: COVID-19 Growth and Change to 2030 provides the strategists, marketers and senior management with the critical information they need to assess the global biosimilar therapeutic peptides market.







This report focuses on the biosimilar therapeutic peptides market which is experiencing strong growth. The report gives a guide to the biosimilar therapeutic peptides market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for biosimilar therapeutic peptides? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Biosimilar Therapeutic Peptides market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider biosimilar therapeutic peptides market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The biosimilar therapeutic peptides market section of the report gives context. It compares the biosimilar therapeutic peptides market with other segments of the biosimilar therapeutic peptides market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, biosimilar therapeutic peptides indicators comparison.

Scope


Markets Covered:


  • By Route Of Administration: Parenteral Route; Transdermal Route; Others
  • By Application: Cancer; Cardiovascular; Central Nervous Systems; Metabolic Disorders; Infection; Hematological Disorders; Gastrointestinal Disorders; Dermatology; Respiratory Disorders
  • By Type: Innovative; Generic

Companies Mentioned:


Eli Lilly; Sanofi; Takeda Pharmaceuticals; Teva Pharmaceuticals; Pfizer Inc.

Countries:


Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions:


Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series:


Five years historic and ten years forecast.

Data:


Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data segmentations:


Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing:


Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Biosimilar Therapeutic Peptides Market

What is the estimated value of the Global Biosimilar Therapeutic Peptides Market?

The Global Biosimilar Therapeutic Peptides Market was estimated to be valued at $0.9 billion in 2021.

What is the growth rate of the Global Biosimilar Therapeutic Peptides Market?

The growth rate of the Global Biosimilar Therapeutic Peptides Market is 26.8%, with an estimated value of $2.3 billion by 2025.

What is the forecasted size of the Global Biosimilar Therapeutic Peptides Market?

The Global Biosimilar Therapeutic Peptides Market is estimated to be worth $2.3 billion by 2025.

Who are the key companies in the Global Biosimilar Therapeutic Peptides Market?

Key companies in the Global Biosimilar Therapeutic Peptides Market include Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline (GSK) and Novo Nordisk A/S.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc.
  • Bachem Holding AG
  • Eli Lilly
  • Hyperion Therapeutics
  • Merck & Co. Inc.
  • PeptiDream

1. Executive Summary2. Biosimilar therapeutic Peptides Market Characteristics3. Biosimilar therapeutic Peptides Market Trends and Strategies4. Impact Of COVID-19 On Biosimilar therapeutic Peptides
5. Biosimilar therapeutic Peptides Market Size and Growth
5.1. Global Biosimilar therapeutic Peptides Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Biosimilar therapeutic Peptides Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market
6. Biosimilar therapeutic Peptides Market Segmentation
6.1. Global Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Parenteral Route
  • Transdermal Route
  • Others
6.2. Global Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Cancer
  • Cardiovascular
  • Central Nervous Systems
  • Metabolic Disorders
  • Infection
  • Hematological Disorders
  • Gastrointestinal Disorders
  • Dermatology
  • Respiratory Disorders
6.3. Global Biosimilar therapeutic Peptides Market, Segmentation by Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Innovative
  • Generic

7. Biosimilar therapeutic Peptides Market Regional and Country Analysis
7.1. Global Biosimilar therapeutic Peptides Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Biosimilar therapeutic Peptides Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8. Asia-Pacific Biosimilar therapeutic Peptides Market
8.1. Asia-Pacific Biosimilar therapeutic Peptides Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
8.3. Asia-Pacific Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
9. China Biosimilar therapeutic Peptides Market
9.1. China Biosimilar therapeutic Peptides Market Overview
9.2. China Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
9.3. China Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion
10. India Biosimilar therapeutic Peptides Market
10.1. India Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
10.2. India Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11. Japan Biosimilar therapeutic Peptides Market
11.1. Japan Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
11.2. Japan Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12. Australia Biosimilar therapeutic Peptides Market
12.1. Australia Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
12.2. Australia Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13. Indonesia Biosimilar therapeutic Peptides Market
13.1. Indonesia Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
13.2. Indonesia Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14. South Korea Biosimilar therapeutic Peptides Market
14.1. South Korea Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
14.2. South Korea Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15. Western Europe Biosimilar therapeutic Peptides Market
15.1. Western Europe Biosimilar therapeutic Peptides Market Overview
15.2. Western Europe Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
15.3. Western Europe Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16. UK Biosimilar therapeutic Peptides Market
16.1. UK Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
16.2. UK Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17. Germany Biosimilar therapeutic Peptides Market
17.1. Germany Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
17.2. Germany Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18. France Biosimilar therapeutic Peptides Market
18.4. France Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
18.5. France Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19. Eastern Europe Biosimilar therapeutic Peptides Market
19.1. Eastern Europe Biosimilar therapeutic Peptides Market Overview
19.2. Eastern Europe Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
19.3. Eastern Europe Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20. Russia Biosimilar therapeutic Peptides Market
20.1. Russia Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
20.2. Russia Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21. North America Biosimilar therapeutic Peptides Market
21.1. North America Biosimilar therapeutic Peptides Market Overview
21.2. North America Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
21.3. North America Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22. USA Biosimilar therapeutic Peptides Market
22.1. USA Biosimilar therapeutic Peptides Market Overview
22.2. USA Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
22.3. USA Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23. South America Biosimilar therapeutic Peptides Market
23.1. South America Biosimilar therapeutic Peptides Market Overview
23.2. South America Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
23.3. South America Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24. Brazil Biosimilar therapeutic Peptides Market
24.1. Brazil Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
24.2. Brazil Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25. Middle East Biosimilar therapeutic Peptides Market
25.1. Middle East Biosimilar therapeutic Peptides Market Overview
25.2. Middle East Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
25.3. Middle East Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26. Africa Biosimilar therapeutic Peptides Market
26.1. Africa Biosimilar therapeutic Peptides Market Overview
26.2. Africa Biosimilar therapeutic Peptides Market, Segmentation by Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
26.3. Africa Biosimilar therapeutic Peptides Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
27. Biosimilar therapeutic Peptides Market Competitive Landscape and Company Profiles
27.1. Biosimilar therapeutic Peptides Market Competitive Landscape
27.2. Biosimilar therapeutic Peptides Market Company Profiles
27.2.1. Eli Lilly
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Sanofi
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Takeda Pharmaceuticals
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Teva Pharmaceuticals
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Pfizer Inc.
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Biosimilar therapeutic Peptides Pipeline Analysis29. Key Mergers and Acquisitions in the Biosimilar therapeutic Peptides Market30. Biosimilar therapeutic Peptides Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc.
  • Bachem Holding AG
  • Eli Lilly
  • Hyperion Therapeutics
  • Merck & Co. Inc.
  • PeptiDream
Major players in the biosimilar therapeutic peptides market are Eli Lilly, Sanofi, Takeda Pharmaceuticals, Teva Pharmaceuticals, Pfizer Inc., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline (GSK), Novartis AG, and Novo Nordisk A/S.

The global biosimilar therapeutic peptides market is expected to grow from $0.76 billion in 2020 to $0.87 billion in 2021 at a compound annual growth rate (CAGR) of 14.5%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $2.25 billion in 2025 at a CAGR of 27%.

The biosimilar therapeutic peptides market consists of sales of biosimilar therapeutic peptides by the companies that are engaged in developing and commercialization of biosimilar peptides drugs for therapeutic applications. Peptide drugs are used as replacement therapies which supplements peptide hormones when the endogenous levels tend to decrease. Biosimilar therapeutic peptides find its application in the treatment of cardiovascular diseases, metabolic diseases, respiratory conditions, cancer, and respiratory diseases.

The biosimilar therapeutic peptides market covered in this report is segmented by route of administration into parenteral route, transdermal route, others and by application into cancer, cardiovascular, central nervous systems, metabolic disorders, infection, hematological disorders, gastrointestinal disorders, dermatology, respiratory disorders.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The long and costly drug approval process is expected to limit the growth of the biosimilar therapeutic peptides market over the upcoming years. The development, approval, and launch of new drugs is an expensive and prolonged procedure that includes expensive research stages. A new drug has to go through four phases of clinical trials and screening by the regulatory body including Food and Drug Administration (FDA) (USA), Medicines and Healthcare Products Regulatory Agency (MHRA) (UK), and Medicines and Healthcare Products Regulatory Agency (MHRA) (India). According to a report of Tufts Center for the Study of Drug Development published by the Journal of Health Economics in 2019, a cost to develop new drugs is $2.6 billion whereas the approval rate for drugs entering clinical trail is less than 12%. Therefore, long and costly drug approvals of new drug candidates are anticipated to hinder the growth of biosimilar therapeutic peptides market.

During the historic period, biosimilar therapeutic peptides market witnessed a growth in research collaborations as well as research funding approvals. Key companies are focusing on collaborations with companies and organizations to enhance their research & developments, expand their product portfolio, and geographical reach. For instance, in January 2020, a UK-based biotechnology company focusing on developing a class of therapeutics based on its proprietary bicyclic peptide technology announced a collaboration with Cancer Research UK to develop BT7401, a new bicycle immune-oncology candidate. Cancer Research UK will fund and sponsor the development of a new candidate. In addition to this, in April 2018, Sapience Therapeutics, Inc., a USA-based biotechnology company focused on research & development on peptide therapeutics announced a research collaboration with the University of Bath (UK) to develop and discover new therapeutic agents for oncology applications. Hence, research collaborations to develop new therapeutic peptides is a major trend in the market.

In October 2019, Zealand Pharma A/S, a Denmark-based biotechnology company specializing in the discovery and development of innovative peptide-based medicines acquired Encycle Therapeutics, Inc. for up to $80 million. The acquisition is expected to strengthen the Zealand Pharma A/S in the peptide therapeutics and in targeting gastrointestinal diseases with the addition of orally delivered preclinical macrocycle peptide. Encycle Therapeutics, Inc., is a Canada-based biotechnology company specializing in unique platform technology that allows the synthesis of macrocyclic peptides demonstrating improved drug-like properties.

The increasing aging population is projected to surge the patients with chronic diseases contributing to the biosimilar therapeutic peptides’ market growth. Elderly people are more prone to various chronic diseases, surging the old age population rapidly across the world and is predicted to continue over the forecast period. According to the World Health Organization (WHO), the world’s population over the age of 60 years is expected to reach 2 billion by the end of 2050, up from 900 million in 2015. In 2018, approximately 125 million people were aged over 80 years or older. Moreover, according to the World Population Prospects: the 2019 Revision, the number of people aged 80 years and above is likely to increase from 143 million in 2019 to 426 million in 2050. Biosimilar therapeutic peptides are used for the treatment of various chronic diseases and cancer. The expected increase in the aging population suffering from various chronic conditions will drive the biosimilar market.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Eli Lilly
  • Sanofi
  • Takeda Pharmaceuticals
  • Teva Pharmaceuticals
  • Pfizer Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline (GSK)
  • Novartis AG
  • Novo Nordisk A/S
  • Ipsen S.A
  • Merck & Co. Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bachem Holding AG
  • CordenPharma International
  • BioPartners
  • Hyperion Therapeutics
  • PeptiDream
  • Bachem Holding AG
  • Lonza Inc.
  • Bristol-Myers Squibb(BMS)
  • PolyPeptide Laboratories
Note: Product cover images may vary from those shown

Loading
LOADING...